Immunizing compositions comprising nucleic acids encoding the HIV-1 matrix protein myristate binding site
OwnerNelson M. Karpinventor
Life of this patent
Estimating the term…
Abstract
The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one covalent binding site of myristate (SEQ ID NOS: 1-3) on the HIV matrix protein. The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NO: 1), messenger RNA, or DNA/RNA (SEQ ID NOS:2-3). DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.
Claims10
An immunizing composition comprising, an expression vector encoding an HIV-1 matrix (MA) protein myristate binding site consisting of SEQ ID NO.:
- 2, a pharmaceutically acceptable carrier, wherein said composition is capable of selectively eliciting a substantially th-1 immune response to HIV-1.
An immunizing composition comprising, a first expression vector encoding an HIV-1 matrix (MA) protein myristate binding site consisting of SEQ ID NO.:
- 2, a pharmaceutically acceptable carrier, and a second expression vector encoding an immune stimulant wherein said composition is capable of selectively eliciting a substantially th-1 immune response to HIV-1.
An immunizing composition comprising, a first expression vector encoding an HIV-1 matrix (MA) protein myristate binding site consisting of SEQ ID NO.:
- 2, a pharmaceutically acceptable carrier, and a second expression vector encoding an adjuvant wherein said composition is capable of selectively eliciting a substantially th-1 immune response to HIV-1.
Dependencies are inferred from the claim text.